Do ACE inhibitors all provide the same outcomes benefits in high-risk cardiovascular patients?

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations

Abstract

The Heart Outcomes Prevention (HOPE) trial was the first to demonstrate the benefits of the angiotensin-converting enzyme (ACE) inhibitor ramipril for high-risk cardiovascular patients. Whether the cardioprotective effects seen in HOPE and other trials are specific to distinct ACE inhibitors remains controversial. Evidence of a lack of class effect for ACE inhibitors has policy and financial implications related to reference pricing by insurers and inclusion on pharmacy formularies. Because head-to-head trials comparing the different ACE inhibitors are unforeseen, clinicians and administrators must rely on secondary-level data and observational studies. Only a handful of studies have sought to address the dispute over a class effect among ACE inhibitors, which is reviewed in this article.

Original languageEnglish
Pages (from-to)286-292
Number of pages7
JournalCurrent Hypertension Reports
Volume10
Issue number4
DOIs
StatePublished - Aug 2008

Fingerprint

Dive into the research topics of 'Do ACE inhibitors all provide the same outcomes benefits in high-risk cardiovascular patients?'. Together they form a unique fingerprint.

Cite this